MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Apellis Pharmaceuticals Cash Conversion Cycle 2011-2026 | APLS
Annual Cash Conversion Cycle Apellis Pharmaceuticals
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 110 | 98.5 | 43.1 | 27.7 | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 110 | 27.7 | 69.9 |
Quarterly Cash Conversion Cycle Apellis Pharmaceuticals
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 115 | 137 | - | 135 | 131 | 126 | - | 116 | 68.4 | 39.9 | - | 32.3 | 38.7 | 52.1 | - | 34.2 | 52.7 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 137 | 32.3 | 82.9 |
Cash Conversion Cycle of other stocks in the Biotechnology industry
| Issuer | Cash Conversion Cycle | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aeterna Zentaris
AEZS
|
-34.3 K | - | 5.93 % | $ 314 M |  Canada |
 |
Adagene
ADAG
|
53.8 | $ 1.9 | -3.11 % | $ 107 M |  China |
 |
Acorda Therapeutics
ACOR
|
117 | - | -24.86 % | $ 820 K |  USA |
 |
AgeX Therapeutics
AGE
|
-8.96 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aytu BioScience
AYTU
|
174 | $ 2.71 | 1.88 % | $ 17 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
166 | $ 25.87 | -0.79 % | $ 1.25 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
12.8 | - | - | $ 40.3 B | USA |
 |
Midatech Pharma plc
MTP
|
82.8 | - | -18.52 % | $ 27.3 M |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
17 | - | -1.52 % | $ 24.7 M | USA |
 |
Brickell Biotech
BBI
|
149 | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Институт стволовых клеток человека
ISKJ
|
104 | - | - | - |  Russia |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Baudax Bio
BXRX
|
-14.3 | - | 0.59 % | $ 63 K | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
8.75 | $ 64.74 | 1.41 % | $ 8.66 B | USA |
 |
CASI Pharmaceuticals
CASI
|
11.9 | $ 0.95 | -0.72 % | $ 129 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-2.15 K | - | - | $ 7.46 M |  Israel |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Celldex Therapeutics
CLDX
|
-6.08 K | $ 25.15 | -1.95 % | $ 1.62 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Albireo Pharma
ALBO
|
-1.55 K | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Catalyst Biosciences
CBIO
|
391 | $ 14.01 | 3.7 % | $ 922 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Biogen
BIIB
|
387 | $ 164.87 | 0.27 % | $ 24 B | USA |
 |
Avid Bioservices
CDMO
|
85.5 | - | - | $ 789 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
54.2 | $ 23.32 | 2.71 % | $ 2.76 B | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |